Journal of Cancer Clinical Trials

Department of Medical Informatics, Northwest Permanente, Portland, OR, USA

Publications

• Mini Review   
  Cannabis-derived Product's Benefits, Drawbacks and Risks as a Cancer Treatment
  Author(s): Dean Sittig*
  
  Patients especially are interested in the use of cannabis products in oncology. The added value of curative or palliative cancer care as well as the potential risks associated with it is not sufficiently demonstrated, so they remain a topic of debate despite the abundance of available research data. By reviewing the most recent research, our goal is to make a recommendation regarding the place of cannabis products in clinical oncology. The characteristics, quality, and pharmacology of various cannabis products are discussed. For quality that can be trusted and replicated, standardization is essential. In comparison to inhalation and drinking tea the mucosal/sublingual route of administration is preferred. Cannabinoids might repress efflux carriers and medication utilizing catalysts, conceivably prompting pharmacokinetic collaborations with anticancer medication.. Read More»
  DOI: 10.37421/2577-0535.2023.8.203

  Abstract HTML PDF